James Amatruda, MD, PhD

Professor of Pediatrics

Image of James Amatruda, MD, PhD
Is this your profile? Click to edit

Overview

James F. Amatruda, MD, PhD is Chief of the Division of Hematology-Oncology and Director of the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles; and Professor of Pediatrics and Medicine at the Keck School of Medicine of the University of Southern California. He received his Bachelor’s degree in Biochemical Sciences from Harvard University and his MD,PhD from Washington University School of Medicine. He did internship and residency training in Internal Medicine at the Brigham and Women’s Hospital in Boston, MA, followed by fellowship training in Medical Oncology at Dana-Farber/Partners Cancer Care in Boston, MA. He was a Postdoctoral Fellow in the laboratory of Dr. Leonard Zon at Boston Children’s Hospital, Harvard Medical School. From 2005-2019, Dr. Amatruda was on the faculty of UT Southwestern Medical Center in Dallas, TX.

Dr. Amatruda is a physician-scientist with a primary research and clinical focus on solid tumors of childhood including sarcomas, germ cell tumors and Wilms tumor. His lab has developed zebrafish models of genetic subtypes of pediatric solid tumors to better define their biology and to use that knowledge to identify and validate novel approaches for improved therapies. He has had long-standing leadership positions in the Children’s Oncology Group; serving as Chair for the Germ Cell Tumor Biology Committee and the Rare Tumors Biology Committee. He also serves as a member of the COG Solid Malignancies Integrated Translational Science Center Steering Committee, and on the Scientific Advisory Boards of the William Guy Forbeck Foundation, the Pablove Foundation, Curing Kids Cancer and the Sam Day Foundation.

Education and Training

  • Harvard University, Cambridge, MA — A.B. — 05/1986 — Biochemical Sciences
  • Washington University, St. Louis, MO — M.D. — 05/1993 — Medicine
  • Washington University, St. Louis, MO — Ph.D. — 05/1993 — Cell Biology
  • Brigham and Women's Hospital, Boston, MA — 06/1996 — Internal Medicine
  • Dana-Farber/Partners Cancer Care, Boston, MA — 06/1999 — Medical Oncology

Research Keywords

  • Childhood cancer
  • Sarcoma
  • Ewing sarcoma
  • Zebrafish models
  • Germ Cell Tumor
  • Wilms tumor
  • microRNA
  • Rhabdomyosarcoma

Publications

  • Modeling of Capicua Family Fusion Oncoprotein-Driven Cancers Reveals Gene-Specific Functionality. Mol Cancer Res. 2026 05 04; 24(5):337-355.. View in PubMed
  • Overlapping genetic etiology of pediatric and adult germ cell tumors. J Natl Cancer Inst. 2026 Mar 30.. View in PubMed
  • Beyond the mouse: 3R-guided alternative animal models transforming cancer research. Mol Cancer. 2026 Mar 26; 25(1).. View in PubMed
  • Droplet Digital PCR and Quantitative RT-PCR Comparison for Circulating miR-371a-3p in Malignant Germ Cell Tumors. J Mol Diagn. 2026 May; 28(5):422-428.. View in PubMed
  • Advancing Preclinical Biology for Ewing Sarcoma: An International Effort. Mol Cancer Ther. 2026 Jan 02; 25(1):48-70.. View in PubMed
  • Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas. Clin Cancer Res. 2025 Dec 01; 31(23):5051-5069.. View in PubMed
  • Origin of Ewing sarcoma by embryonic reprogramming of neural crest to mesoderm. Cell Rep. 2025 Oct 28; 44(10):116376.. View in PubMed
  • Outcome of Children With Intermediate-Risk Extracranial Malignant Germ Cell Tumors by Response Status at the End of Induction Chemotherapy: A Report From the Children’s Oncology Group. Pediatr Blood Cancer. 2025 Dec; 72(12):e32033.. View in PubMed
  • PD-L1 Expression is Mediated by microRNA Processing, Wnt/β-Catenin Signaling, and Chemotherapy in Wilms Tumor. Pediatr Blood Cancer. 2025 Sep; 72(9):e31852.. View in PubMed
  • Robust statistical assessment of Oncogenotype to Organotropism translation in xenografted zebrafish. bioRxiv. 2025 Jun 01.. View in PubMed